Third Quarter 2026
Filed Nov 3, 2026IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
IDEAYA completed its first NDA submission for darovasertib and maintained cash runway guidance into 2030, but quarterly operating expenses and net loss increased versus the prior quarter, while the company stopped enrollment and will close the Phase 3 OptimUM-010 trial because of site activation and enrollment challenges.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, three months ended September 30, 2026 (in thousands)GAAP | $10.24M | – | – |
| Research and development expense, three months ended September 30, 2026 (in thousands)GAAP | 121.6M | – | – |
| General and administrative expense, three months ended September 30, 2026 (in thousands)GAAP | 26.30M | – | – |
| Total operating expenses, three months ended September 30, 2026 (in thousands)GAAP | 147.9M | – | – |
| Loss from operations, three months ended September 30, 2026 (in thousands)GAAP | −137.6M | – | – |
| Interest income and other income, net, three months ended September 30, 2026 (in thousands)GAAP | 11.88M | – | – |
| Net loss, three months ended September 30, 2026 (in thousands)GAAP | −125.7M | – | – |
| Unrealized losses on marketable securities, three months ended September 30, 2026 (in thousands)GAAP | −3.21M | – | – |
| Comprehensive loss, three months ended September 30, 2026 (in thousands)GAAP | −$129.0M | – | – |
| Net loss per share attributable to common stockholders, basic, three months ended September 30, 2026GAAP | $ (1.22) | – | – |
| Weighted-average number of shares outstanding, basic, three months ended September 30, 2026GAAP | 102,944,175 | – | – |
| Net loss per share attributable to common stockholders, diluted, three months ended September 30, 2026GAAP | $ (1.22) | – | – |
| Weighted-average number of shares outstanding, diluted, three months ended September 30, 2026GAAP | 102,944,175 | – | – |
| Total stock-based compensation expense, three months ended September 30, 2026GAAP | $17.7M | – | – |
| Collaboration revenue, nine months ended September 30, 2026 (in thousands)GAAP | $25.66M | – | – |
| Research and development expense, nine months ended September 30, 2026 (in thousands)GAAP | 326.0M | – | – |
| General and administrative expense, nine months ended September 30, 2026 (in thousands)GAAP | 68.14M | – | – |
| Total operating expenses, nine months ended September 30, 2026 (in thousands)GAAP | 394.1M | – | – |
| Loss from operations, nine months ended September 30, 2026 (in thousands)GAAP | −368.5M | – | – |
| Interest income and other income, net, nine months ended September 30, 2026 (in thousands)GAAP | 31.73M | – | – |
| Net loss, nine months ended September 30, 2026 (in thousands)GAAP | −336.7M | – | – |
| Unrealized losses on marketable securities, nine months ended September 30, 2026 (in thousands)GAAP | −7.15M | – | – |
| Comprehensive loss, nine months ended September 30, 2026 (in thousands)GAAP | −$343.9M | – | – |
| Net loss per share attributable to common stockholders, basic, nine months ended September 30, 2026GAAP | $ (3.56) | – | – |
| Weighted-average number of shares outstanding, basic, nine months ended September 30, 2026GAAP | 94,620,638 | – | – |
| Net loss per share attributable to common stockholders, diluted, nine months ended September 30, 2026GAAP | $ (3.56) | – | – |
| Weighted-average number of shares outstanding, diluted, nine months ended September 30, 2026GAAP | 94,620,638 | – | – |
| Cash and cash equivalents and short-term and long-term marketable securities as of September 30, 2026 (in thousands)GAAP | $1.15B | – | – |
| Total assets as of September 30, 2026 (in thousands)GAAP | 1.22B | – | – |
| Total liabilities as of September 30, 2026 (in thousands)GAAP | 124.0M | – | – |
| Total liabilities and stockholders' equity as of September 30, 2026 (in thousands)GAAP | $1.22B | – | – |
| Remaining balance for research and development services performance obligations as of September 30, 2026other | $139.8M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
into 2030 outlook
- NoteCash runway guidance into 2030 remains unchanged based on the current operating plan.
- NoteInitial clinical data from IDEAYA's global Phase 1/2 trial of IDE849 monotherapy in extensive-stage SCLC and NEC is expected by the end of 2026 or early in 2027.
- NoteIDEAYA plans to initiate two Phase 3 registrational trials with IDE849 in ES-SCLC and NEC by year end.
- NoteIDEAYA is targeting initiation of a Phase 1 trial of IDE892 in combination with RG6505 by the end of 2026.
- NoteExpansion of the IDE892 and IDE397 combination is planned by the first half of 2027.
- NoteIDEAYA plans to provide initial clinical data from the IDE034 Phase 1 dose escalation trial in 2027.
What drove it
- Third-quarter collaboration revenue was recognized for performance obligations satisfied through September 30, 2026 related to research and development services recognized over time under the Servier exclusive license agreement for darovasertib.
- R&D expense increased primarily because of higher clinical trial and development costs and personnel-related expenses supporting IDEAYA's programs.
- G&A expense increased primarily because of higher personnel-related expenses supporting company growth and darovasertib commercial preparation activities.
- IDEAYA successfully submitted an NDA to the FDA during the third quarter for darovasertib plus crizotinib in metastatic uveal melanoma under the RTOR program.
- IDEAYA initiated the global Phase 3 OptimUM-011 trial in adjuvant primary uveal melanoma following completion of a Type C meeting with the FDA.
Concerns
- IDEAYA decided to stop enrollment and close the Phase 3 OptimUM-010 trial due to ongoing site activation and enrollment challenges.
- The company reported a net loss of $ (125,749) (in thousands) for the three months ended September 30, 2026.
- Research and development expense was 121,576 (in thousands) and total operating expenses were 147,874 (in thousands) for the three months ended September 30, 2026.
- Clinical findings may change with additional follow-up, and early results, small cohorts and subgroup analyses may not predict outcomes in larger or subsequent studies.
What to watch
- FDA review of the NDA for darovasertib plus crizotinib in metastatic uveal melanoma.
- Initial clinical data from IDEAYA's global Phase 1/2 IDE849 monotherapy trial in extensive-stage SCLC and NEC, expected by the end of 2026 or early in 2027.
- Planned initiation of Phase 3 registrational trials for IDE849 in ES-SCLC and NEC by year end.
- Enrollment and execution of the approximately 450-patient Phase 3 OptimUM-011 adjuvant trial.
- IDEAYA's R&D Day on November 16, 2026, including new preclinical data on MTAP/CDKN2A deficiency in KRAS-mutant cancers.
- Execution of the Roche and Genentech clinical collaborations evaluating IDE892 combination strategies.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were approximately $1.15 billion as of September 30, 2026, compared to $1.24 billion as of June 30, 2026.
- The decrease was primarily driven by net cash used in operations.
- Cash and cash equivalents and short-term and long-term marketable securities were $ 1,150,827 (in thousands) as of September 30, 2026, versus $ 1,049,685 (in thousands) as of December 31, 2025.
- Total assets were 1,216,020 (in thousands) and total liabilities were 123,957 (in thousands) as of September 30, 2026.
Analysis
IDEAYA's third quarter was defined by regulatory and pipeline execution rather than product revenue. The company completed its first NDA submission for darovasertib plus crizotinib in metastatic uveal melanoma under the FDA's RTOR program. Collaboration revenue was $ 10,242 (in thousands) for the three months ended September 30, 2026, compared with $ 8,857 (in thousands) for the three months ended June 30, 2026. The revenue was tied to R&D services under the Servier exclusive license agreement, and the company reported $139.8 million of remaining R&D services performance obligations related to anticipated clinical-development cost reimbursements.
Spending increased during the quarter as IDEAYA advanced its pipeline and prepared darovasertib commercially. R&D expense was 121,576 (in thousands), compared with 108,689 (in thousands) in the preceding quarter, while G&A expense was 26,298 (in thousands), compared with 22,459 (in thousands). Management attributed the R&D increase to clinical trial, development and personnel costs, and attributed the G&A increase to personnel costs, company growth and darovasertib commercial preparation. Loss from operations was (137,632) (in thousands), and net loss was (125,749) (in thousands), versus (112,452) (in thousands) in the prior quarter.
The pipeline update included supportive clinical data presentations for darovasertib and IDE849, as well as new trial activity across the ADC, MTAP and KAT6/7 programs. IDEAYA also initiated OptimUM-011, a global Phase 3 registrational trial in adjuvant primary uveal melanoma that is expected to enroll approximately 450 patients. In contrast, the company stopped enrollment and will close the Phase 3 OptimUM-010 trial because of site activation and enrollment challenges. IDEAYA expects estimated cost savings of $100-125 million from the closure and intends to reallocate resources to other pipeline programs, including potential registrational trials for IDE849 and IDE892.
Liquidity remains the principal financial support for the development plan. Cash, cash equivalents and marketable securities were approximately $1.15 billion as of September 30, 2026, compared with $1.24 billion as of June 30, 2026, with the decline primarily driven by net cash used in operations. The company maintained its cash-runway guidance into 2030 based on its current operating plan. The next material execution points are the FDA review of the darovasertib NDA, planned IDE849 Phase 3 trial starts by year end, and initial data from IDEAYA's global IDE849 Phase 1/2 study expected by the end of 2026 or early in 2027.
Management, verbatim
We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma.
Yujiro S. Hata, Chief Executive Officer of IDEAYA
Looking ahead, we are excited to share new preclinical data on our extensive MTAP/CDKN2A franchise in RAS-mutant cancers that provides the scientific rationale in support of the two clinical collaborations we established with Roche and Genentech.
Yujiro S. Hata, Chief Executive Officer of IDEAYA
Not in the filing
stated, not guessed- Prior-year comparison for third-quarter collaboration revenue, operating expenses, loss from operations, net loss, comprehensive loss, EPS and weighted-average shares was not provided.
- Percentage year-over-year and quarter-over-quarter changes for reported financial metrics were not provided.
- Gross profit, gross margin, operating margin, tax expense, tax rate, operating cash flow, free cash flow, capital expenditures, debt, share repurchases and dividends were not provided.
- Non-GAAP financial measures were not provided.
- Segment revenue and segment profitability were not provided.
- Prior outlook was not provided, so no comparison of reported results with prior guidance is available.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.